Wall Street Journal Quotes Craig Bleifer on the Future of the FDA’s Project Optimus
Contact:
Akin health care & life sciences partner Craig Bleifer speaks to the Wall Street Journal about the future of Project Optimus, an FDA program launched in 2021 aimed at reforming the process for setting doses for new cancer drugs. The article, titled “FDA Wants Safer Cancer Drugs, But Some Startups Fear Unintended Consequences,” explores the potential for these reforms to increase costs and extend drug development times, and whether those changes could negatively impact smaller companies and startups.
Despite those concerns, Craig notes that Project Optimus is not as contentious as other issues like drug pricing and is unlikely to change after the November election.
People Mentioned in This News
© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.